Sibylla Biotech

Sibylla Biotech is a private, preclinical-stage company developing a new class of small molecule degraders based on its proprietary PPI-FIT platform. Founded in 2016 as a spin-off from leading Italian research institutions, the company leverages advanced physics-based simulations and its Oneiros AI platform to identify and drug transient folding intermediates of proteins. With strategic collaborations already established with major pharmaceutical companies like Ono Pharmaceutical and Takeda, and a €23 million Series A financing secured in 2022, Sibylla is positioning itself at the forefront of next-generation targeted protein degradation.

PPI-FIT (Pharmacological Protein Inactivation by Folding Intermediates Targeting) platform, powered by physics-based protein folding simulations and the Oneiros AI platform, to discover small molecule degraders that bind transient folding intermediates.

Sibylla competes in the targeted protein degradation (TPD) space against companies developing PROTACs and molecular glues. Its key differentiation is targeting folding intermediates rather than native proteins, potentially accessing a unique target space, but it is earlier-stage than public leaders like Arvinas and Kymera.